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One Sentence Summary:  RYR1 mutations cause prolonged bleeding by affecting smooth 
muscle cell calcium regulation, potentially treatable through administration of dantrolene.  
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Abstract 
Bleeding abnormalities have been reported in some patients carrying gain of function RYR1 
mutations related Malignant Hyperthermia. We sought to determine the frequency and molecular 
basis for this symptom.  We found that some RYR1–mutated patients had abnormal bleeding 
scores, whereas their healthy relatives did not. Knock-in mice with the Malignant Hyperthermia 
Susceptibility RYR1 mutation Y522S (MHS RYR1Y522S) had bleeding times that were 3 times 
longer than their wild type littermates. Primary vascular smooth muscle cells from RYR1Y522S 
knock-in mice exhibited a higher frequency of subplasmalemmal Ca2+ sparks leading to a more 
negative resting membrane potential. The bleeding defect of RYR1Y522S mice and of one patient 
could be reversed by treatment with the ryanodine receptor 1 antagonist dantrolene, and Ca2+ 
sparks in primary vascular smooth muscle cells from the RYR1Y522S mice were blocked by 
ryanodine or dantrolene. Thus, RYR1 mutations cause prolonged bleeding by altering vascular 
smooth muscle cell function. The reversibility of the bleeding phenotype emphasizes the potential 
therapeutic value of dantrolene in the treatment of such bleeding disorders. 
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Introduction 
Hemostasis is a stepwise process that causes bleeding to stop and can be grossly divided 
into primary and secondary hemostasis and three distinct stages. Primary hemostasis comprises 
(i) an instant vascular response to injury, leading to transient vasoconstriction limiting immediate 
blood loss, and (ii) platelet activation and aggregation, prompted by plasma Von Willebrand 
factor and sustained through platelet granule release that also enhances the initial 
vasoconstriction. Primary hemostasis results in formation of a platelet plug aimed at provisionally 
stopping the bleeding. Secondary hemostasis involves (iii) the sequential activation of clotting 
factors present in the plasma in an inactive state through a cascade of reactions, ultimately 
leading to the formation of a fiber-like mesh called fibrin that surrounds the provisional platelet 
plug and causes definite blood coagulation (1).   
Bleeding disorders are clinically and genetically heterogeneous and may affect all aspects 
of hemostasis. The most common causes are partial deficiencies of coagulation factors and 
fibrinolytic proteins, deficiencies in von Willebrand factor and platelet or connective tissue 
disorders (1). Nevertheless mild bleeding disorders are common in the general population but 
their precise incidence as well as their genetic background remain often unresolved (2,3). 
Mutations in RYR1, the gene encoding the skeletal muscle Ca2+ channel ryanodine 
receptor 1 (RyR1), have a calculated frequency of 1:2000-1:3000 (4). Dominant RYR1 mutations 
are commonly associated with Malignant Hyperthermia (MH), a severe pharmacogenetic reaction 
to halogenated anesthetics and muscle relaxants, exertional rhabdomyolysis/myalgia (ERM) (5) 
and the congenital myopathy Central Core Disease (CCD). Recessive RYR1 mutations have been 
associated with the congenital myopathies Multi-minicore Disease (MmD), Centronuclear 
Myopathy (CNM) and Congenital Fiber Type Disproportion (CFTD) (6-8). Bleeding 
abnormalities have been reported in isolated patients with MH Susceptibility (MHS) (9-11) and 
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homozygous mouse embryos knocked in for the Malignant Hyperthermia Susceptibility RYR1 
mutation Y522S (RYR1Y522S) display massive edema and subcutaneous blood effusions at birth, 
suggestive of a severe bleeding disorder with antenatal onset (12).  
Vascular smooth muscle cells play an important role in primary hemostasis and changes 
in the intracellular Ca2+ concentrations play a central mechanism regulating their relaxation and 
contraction (13). In addition to InsP3Rs, smooth muscle cells also express the three different RyR 
isoforms (13-17), and their Ca2+ homeostasis is more elaborated compared to many other 
excitable cell types. While InsP3R act as channels releasing Ca2+ from the endo(sarco)plasmic 
reticulum leading to smooth muscle cell contraction, the specific role of RyRs is more complex, 
and in contrast to striated muscle, RyRs are involved in smooth muscle cell relaxation (13,18,19). 
We hypothesized that there may be a correlation between the presence of dominant, Malignant 
Hyperthermia-related RYR1 mutations and mild bleeding abnormalities. 
In the present study we investigated the potential relationship between a mild bleeding 
disorder and the presence of dominant, gain of function RYR1 mutations; we then used the 
heterozygous RYR1Y522S mouse model to study the mechanism linking prolonged bleeding time 
to Ca2+ homeostasis in isolated smooth muscle cells. Our results indicated that gain-of-function 
RYR1 mutations mainly affected Ca2+ homeostasis of smooth muscle cells by increasing “Spark” 
(spontaneous calcium release events) activity; we also demonstrate that administration of the 
specific RyR1 antagonist dantrolene, which is clinically approved for the treatment of Malignant 
Hyperthermia reactions (20-21), reversed the bleeding phenotype by decreasing spark activity in 
vascular smooth muscle cells. 
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Results 
Bleeding abnormalities in human subjects with RYR1 mutations 
To investigate bleeding in RYR1-associated myopathies, we invited RYR1-mutated 
individuals and their non-mutated relatives to complete a standardized questionnaire ((Molecular 
and Clinical Markers for the Diagnosis and Management of Type 1 Von Willebrand’s Disease 
also known as MCMDM-1VWD)) validated for the evaluation of bleeding disorders (Table 1). 
Patients had neuromuscular features of Malignant Hyperthermia, ERM, a congenital myopathy 
(Central Core Disease or Multiminicore Disease) or a combination of these features, associated 
mainly with dominant heterozygous RYR1 missense mutations. A proportion of patients were 
compound heterozygous for 2 allelic RYR1 mutations, reflecting the fact that some RYR1 
mutations behave as dominant with regards to Malignant Hyperthermia, but as recessives with 
regards to the congenital myopathy phenotype. The neuromuscular features of patients from 
families 1, 2, 4, 6, 7, 8 and of their relatives have been previously reported. (5,22-24). MCMDM-
1VWD bleeding questionnaires were obtained from 24 RYR1-mutated patients (12 females, 12 
males) and 14 relatives without the familial RYR1 mutation (4 females, 10 males). Symptoms of 
abnormal bleeding were common in RYR1-mutated individuals, characterized by severe 
menorrhagia and postpartum hemorrhage in females and milder symptoms of epistaxis and easy 
bruising in males. One male patient reported spontaneous hematomas in association with muscle 
cramps, while one female patient reported an additional history of recurrent and unexplained 
miscarriages. Improvement of menorrhagia was reported in one female (Patient 4.2) after 
prescription of sodium dantrolene, the specific RyR1 antagonist used clinically to reverse acute 
Malignant Hyperthermia reactions (20,21), for her severe ERM. Baseline hematological studies 
including evaluation of clotting factors and platelet aggregation studies were normal in all 
patients with symptoms of increased bleeding, except in patients 2.6 and 2.7 in whom abnormal 
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von Willebrand factor (vWF) levels were found, and patient 5.1 who had evidence of abnormal 
platelet function; bleeding scores from these patients were excluded from further statistical 
analysis as an alternative hematological diagnosis could not be confidently ruled out. Eight out of 
twenty-one (38%) patients included in the statistical analysis had a pathological bleeding score 
(≥4) on the questionnaire compared to 0/14 (0%) of controls (P=0.0118, Fisher exact testing with 
2-tailed P value). The mean bleeding score for patients is shown in Figure 1A 	  
 
A mouse model knocked in for a human RYR1 mutation associated with Malignant 
Hyperthermia Susceptibility shows prolonged bleeding times. 
To gain mechanistic insight linking RYR1 mutations to bleeding, we used the 
heterozygous RYR1Y522S Malignant Hyperthermia Susceptible mouse (12). Applying a 
standardized test to accurately determine bleeding times in mice (25), we demonstrate that 
bleeding times in RYR1Y522S mice are 2-3 longer than in their WT littermates (see Figure 1B for 
bleeding times in male mice and Supplementary Figure 1 for bleeding times in female mice). 
Intraperitoneal dantrolene administration to wild-type mice prior to the bleeding test did not 
affect bleeding times. However, pre-treatment of RYR1Y522S mice with dantrolene reduced 
bleeding to the same times as those seen in their wild-type littermates. This effect was not 
observed in mice treated with vehicle alone (Figure 1 B).  
Bleeding times depend on the contraction of injured blood vessels, platelet number and 
function, and the activation of circulating clotting factors. We have previously not found a 
difference in the number and function of circulating platelets between wild-type and RYR1Y522S 
mice (26). RyR1 is not detectable in platelets, virtually excluding disturbed platelet function as a 
potential cause for the bleeding disorder. Since WT and RYR1Y522S knock-in littermates only 
differ in their RYR1, we hypothesized that these differences in bleeding times could be due to 
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changes in the contraction/relaxation properties of the smooth muscle cells lining the blood 
vessels. Because of their small size (with a diameter of 0.26±0.03 mm) we could not accurately 
measure changes in vessel diameter, which would be a direct indication of contraction/relaxation. 
Instead we used Pulsed-Wave Doppler to assess velocity of blood flow (27,28), at a point 1 cm 
upstream from the incision of the tail artery, at a constant blood pressure (see Supplementary 
Figure 2 for systolic blood pressure and heart beat values). Velocity of blood is inversely related 
to vessel diameter (29) and therefore changes in velocity reflect changes in the 
contraction/relaxation status of smooth muscle cells. Under baseline conditions there were no 
differences in blood flow velocity through the caudal artery between WT and RYR1Y522S mice 
(Figure 1C). Interestingly however, in response to injury and more specifically at 8-10 minutes 
post incision, the velocity of blood flow in the tail artery of WT mice was significantly faster than 
in that of RYR1Y522S mice. This result indirectly indicates that vasoconstriction occurs to a larger 
extent in the tail arteries of WT than in RYR1Y522S mice. 
We next verified the expression of RYR1 in primary arterial vascular smooth muscle cells 
by performing qPCR experiments using primers specific for mouse RYR1 and normalized the 
expression levels in the different muscle tissues to desmin (DES), as this protein is present in 
skeletal and smooth muscle cells (30). Mouse aorta and tail artery express the RYR1 transcript, 
though as expected, to a much lower extent than skeletal muscle (Figure 2A) and the presence of 
the RYR1Y522S mutation in the heterozygous state does not affect the expression levels of RYR1 
(Figure 2B) nor of RYR2 and RYR3 (Supplementary Figure 3). RT-PCR on mRNA isolated from 
tail arteries, confirm the expression of a mutated transcript in the heterozygous RYR1Y522S mice 
(Figure 2C). Confocal immunohistochemical analysis on isolated primary vascular smooth 
muscle cells confirmed the presence of the specific smooth muscle marker actin (Fig. 2D, central 
panels). Analysis of the subcellular distribution of RyR1 using an antibody that under our 
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experimental conditions does not cross react with RyR2 (Supplementary figure 4) showed that 
RyR1s are localized close to the plasma membrane (Figure 2E, red). This distribution is 
compatible with that of the voltage sensing dihydropyridine receptor Cav1.2 which is found on 
the plasma membrane of vascular smooth muscle cells (figure 2E, green) (31-33). The subcellular 
distribution of RyR1 in isolated primary vascular smooth muscle cells is similar to that reported 
in pulmonary artery smooth muscle cells and in vas deferens (33-35); in the latter cells localized 
RyR1-mediated calcium release from subplasmalemmal stores causes activation of BK channels 
resulting in cellular hyperpolarization leading to vasodilation (35, 36).  
 
Calcium homeostasis in vascular smooth muscle cells isolated from the RYR1Y522S mouse is 
significantly different compared to that of their wild-type littermates 
To investigate how RYR1 mutations affect Ca2+ homeostasis, we isolated primary vascular 
smooth muscle cells from mouse-tail arteries. We used this cellular model since bleeding times 
have been assessed on this tissue and these cells are responsible for the control of the vasomotor 
activity in the tail (37). No changes in the resting Ca2+ concentration were observed between 
primary vascular smooth muscle cells isolated from wild-type and RYR1Y522S mice (Fig.3 A and 
B), though the latter cells showed significantly smaller total rapidly releasable Ca2+ stores 
compared to those isolated from wild-type littermates  (Fig.3C). In smooth muscle cells, local 
calcium release events termed “Ca2+ sparks” have been ascribed to the opening of single or 
clusters of RyR channels; though they have little or no direct effect on contraction, they indirectly 
lead to vasodilation through activation of BK channels (13,18). We studied spark activity in 
isolated primary vascular smooth muscle cells loaded with the fast calcium dye Fluo-4 (Fig. 3D). 
A representative image of an isolated tail arterial smooth muscle cell is displayed on the top panel 
of Figure 3D (left) and the same cell loaded with Fluo-4 is shown on the right panel. 
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Representative linescan images (x,t) of Ca2+ sparks observed in WT and RYR1Y522S mice are 
shown on the bottom of Figure 3D. The grey images have been pseudocoloured and normalized 
to F/F0. A trace showing the detailed time course of several sparks in WT and RYR1Y522S cells is 
shown beneath each linescan image. The frequency of sparks (sparks/image) is given in Figure 3 
E and representative videos of sparks occurring in cells from WT and RYR1Y522S mice are shown 
in Supplementary Videos 1 and 2, respectively. Detailed analysis of spark amplitude and kinetics 
revealed small but significant differences between cells isolated from WT and RYR1Y522S knock 
in mice (Supplementary Table 1) .  
We next used several drugs including RyR1 blockers and the InsP3R antagonist 
Xestospongin C to determine the origin of these spontaneous Ca2+ release event. Sparks were 
extinguished in wild-type and RYR1Y522S primary vascular smooth muscle cells by pre-
incubation with Ryanodine (Figure 3E and Supplementary Video 3). Additionally, pre-incubation 
with dantrolene significantly decreased spark frequency in both WT and RYR1Y522S cells (Figure 
3 E and Supplementary Video 4). This effect was not observed when cells were incubated with the 
InsP3 antagonist Xestospongin C (Video 5). These results indicated that RyR1 was present in 
primary vascular smooth muscle cells, that RYR1 mutations leading to MHS were not only 
present in skeletal muscle but also in arterial smooth muscle cells, and that the RYR1Y522S 
mutation increased the frequency of spark events. In skeletal muscle, RYR1 mutations associated 
with MHS are gain-of-function mutations leading to an increased sensitivity to activating stimuli, 
resulting in prolonged and sustained muscle contractions (38-41). Our results suggested that a 
similar mechanism did not operate in smooth muscle cells since RYR1 mutations caused 
prolonged and not shorter bleeding times, the latter of which would be expected if mutated RyR1 
caused a gain of function in primary vascular smooth muscle cells. In skeletal muscle excitation-
contraction coupling depends on the mechanical interaction between the voltage sensing 
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dihydropyridine receptor and the RyR1 (42), whereas in smooth muscle cells the functional unit 
is made up of dihydropyridine receptors, ryanodine receptors and BKCa channels (13,18).  RyR 
dependent Ca2+ sparks activate BKCa channels causing plasma membrane hyperpolarization 
thereby decreasing Ca2+ influx through the dihydropyridine receptor and leading to smooth 
muscle relaxation (13,18). We found that vascular smooth muscle cells from RYR1Y522S mice 
were significantly more hyperpolarized than those from wild-type mice, which had membrane 
potentials in line with previous reports (18) (Figure 4A). Furthermore, the membrane potential of 
cells from the RYR1Y522S mice was reverted to control levels after treatment with dantrolene 
(Figure 4A).  
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Discussion 
In the present study we demonstrate that gain-of-function RYR1 mutations associated with 
MH and/or exertional rhabdomyolysis cause a mild but distinct bleeding disorder in humans and 
a corresponding phenotype in a murine model of Malignant Hyperthermia, by affecting vascular 
smooth muscle cell calcium homeostasis. A model showing how RYR1 mutations affect smooth 
muscle cell contraction is shown in Figure 4B. Characteristic features of the human bleeding 
phenotype were female preponderance, presentation with marked menorrhagia, postpartum 
bleeding and a history of miscarriages in the context of normal coagulation tests. Although in our 
study we evaluated a relatively small sample of RYR1-mutated patients and controls, the clinical 
data are consistent with the data obtained from the corresponding mouse model carrying the 
murine equivalent of a human Malignant Hyperthermia-related RYR1 mutation (12). We are 
aware that the bleeding times of RYR1Y522S mice show large variation but this may reflect 
different extents of contraction of the skeletal muscles within the mouse tail when placed at 37°C. 
Alternatively it may be due to intrinsic structural properties of the RyR complex rather than argue 
against the main conclusions of our paper. The variability of bleeding times may result from the 
protomeric composition of the RyR1 protein complex expressed in tail smooth muscle cells 
obtained from the RyR1Y522S mice. A variation in the proportion of protomers encoded by WT 
and mutated alleles within the tetrameric RyR1 Ca2+ channel complex affects the biophysical 
properties of the RyR1 complex (43) and therefore may account for the variability of the calcium 
signals responsible for vascular responses. This explanation is in agreement with the data 
obtained from wild type mice, which exhibit much more consistent bleeding times, because of the 
homogeneous protomeric composition within the RyR1 tetrameric protein complex. The data we 
obtained from mice also corresponds to findings in humans, where bleeding scores derived from 
the MCMDM-1VWD questionnaire showed a higher mean bleeding score but also greater 
	   13	  
variability in RYR1-mutated patients compared to relatives without the familial RYR1 mutation.  
Prolonged bleeding times in the RYR1Y522S mice and in one patient, were reversed by 
administration of the specific RyR1 antagonist dantrolene, strongly supporting an association 
between the observed bleeding phenotype and the RYR1 mutant state.  These results provide the 
proof of concept that dantrolene could be administered as a pharmacological treatment for RYR1-
related bleeding disorders and, potentially, other causes of prolonged bleeding due to impaired 
vascular smooth muscle cell contractility rather than primary platelet or coagulation factor 
abnormalities.. Considering that carriers of Malignant Hyperthermia -associated RYR1 mutations 
are frequent (1:2000-1:3000)(4) but often asymptomatic unless exposed to triggering agents, such 
mutations may account for common mild bleeding abnormalities in humans that are currently 
without genetic explanation. Of note, we found evidence of abnormal platelet function (n=1) and 
borderline reduced vWF levels (n=2) in 3 RYR1-mutated patients within our cohort; these patients 
were not considered for the final statistical analysis as we could not exclude a primary platelet or 
vWF abnormality as an alternative explanation for the observed bleeding phenotype. However, 
similar findings of mildly abnormal platelet function and vWF levels have been reported in other 
non-hematological disorders associated with prolonged bleeding such as collagen disorders (44) 
or Noonan syndrome (45), where the primary defect does not concern platelets or coagulation 
factors and may therefore well be a secondary feature also in the RYR1-related bleeding disorder 
reported in this study.     
Our observations are in keeping with emerging knowledge concerning the dynamic and 
complex role of BKCa channels and RyR in tissue-specific vasoregulation: a recent study in 
mesenteric resistance arteries demonstrates that pressure-induced RyR activation has a strong 
vasodilatory effect, mediated by Ca2+–induced activation of BKCa channels and, possibly, Ca2+–
induced inactivation of L-type voltage-dependent Ca2+ channels (VDCCs) (46). Considering that 
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RyR2 rather than RyR1 is the predominant RyR isoform in murine mesenteric arteries (47), the 
observation of a RYR1-associated arterial smooth muscle cell phenotype seems unexpected. 
However, in this context distinct spatial distribution may be more important than relative amount 
of RyR isoform expression: as we have demonstrated in murine arterial smooth muscle cells, 
RyR1s are predominantly found subsarcolemmally, and altered activity of the mutant RyR1s may 
be more consequential because of their close proximity to BKCa channels. We can also not 
exclude the possibility that the release of Ca2+ from mutated RyR1 channels may facilitate the 
opening of adjacent RyR2 channels via the regenerative Ca2+ induced Ca2+ release mechanism 
(48).  
Our study reports a non-neuromuscular phenotype, that is abnormal bleeding, in RYR1-
related myopathies and is likely to inform the surveillance and anticipatory management of 
patients affected by these conditions. Considering that RyR1 is expressed in a wide range of 
tissues, non-neuromuscular manifestations of RYR1 mutations are not unexpected but may have 
been overlooked, because they are mild and/or involve symptoms that are not necessarily 
considered part of a neuromuscular disorder. The marked female preponderance in our series with 
severe menorrhagia and/or post-partum hemorrhage raises the question of more extensive smooth 
muscle cell involvement in RYR1-related myopathies. Such additional smooth muscle cell 
involvement may confound the observed bleeding phenotype, in a gender-specific manner in 
particular on the uterine level, considering that smooth muscle cells also play an important role in 
uterine vasoregulation and myometrial contraction (49,50). Indeed, patients from two of our 
families reported prominent bowel and bladder involvement (urinary incontinence, vesicoureteral 
reflux, “spastic colon”), suggesting more widespread smooth muscle cell involvement also in 
keeping with a previously documented role of both RyRs and BKCa channels in bladder smooth 
muscle signaling (51). Although clearly beyond the aim of the present study whose goal was to 
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specifically investigate bleeding abnormalities in patients with RYR1 mutations, these 
observations should prompt future investigations into the association between RYR1 mutations 
and a more generalized smooth muscle dysfunction both on the clinical and cellular level.                
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Materials and Methods 
Patients: Patients were identified through the participating tertiary neuromuscular and malignant 
hyperthermia (MH) centers. Genetic testing and haematological studies including evaluation of 
clotting factors and platelet aggregation were performed as part of the routine diagnostic workup. 
Patients were invited to complete the MCMDM-1VWD (= Molecular and Clinical Markers for 
the Diagnosis and Management of Type 1 Von Willebrand’s Disease) bleeding questionnaire, a 
validated and widely used diagnostic tool in the evaluation of bleeding disorders (52). 
MCMDM1-VWD bleeding questionnaires were scored independently by two clinicians blinded 
to the genetic status (mutated vs non-mutated) of the proband. The study received UK Research 
Ethics Committee approval (15/WS/204, granted by the West of Scotland REC 5). Patients gave 
informed consent for anonymized publication of their clinical information. 
Animal Model: Experiments were carried out on 7-12 week old heterozygous RYR1Y522S knock-
in mice and their wild type littermates. The mouse model was generated by Chelu et al. (12) and 
was a generous gift of Dr. Susan Hamilton, Baylor College of Medicine, Houston, Texas USA. 
Experimental procedures were approved by the Veterinary Cantonal Authorities (Permit numbers 
1728 and 1729).  
Bleeding time assay: Bleeding time was determined according to Liu et al. (25). Intraperitoneal 
injections with dantrolene (10 mg/kg) or vehicle alone (saline solution) were administered 1 h 
prior to bleeding time determination. 
Pulsed-wave Doppler: Male mice (15-20 weeks old) were lightly anaesthetized with 
Ketamine/Xylazine (95mg/Kg Ketamine +10 mg/kg Xylazine) and placed on a heated blanket at 
26 °C. Blood flow velocity in the tail artery was measured using a Pulse-Wave Doppler 
ultrasound system (Vevo 2100, VisualSonics Inc., Toronto, Canada) at high frequency (32 MHz, 
MS 550D transducer). The probe was positioned where a consistent signal could be detected at 
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the proximal end of the tail, approximately 1 cm from the base of the tail. Velocity of blood flow 
was measured before and at 6 time points after an incision was made on the tail artery; 
measurements were made 1 cm upstream from the incision site. The velocity was measured 
during 5 consecutive cardiac cycles and the mean blood flow velocity per mouse was plotted at 
each time point before and after incision. The experimenters were blinded and had no prior 
knowledge of the genotype of the mice. Data were analyzed and plotted using the GraphPad 
Prism V 6.0 and Origin Pro 8.6.0 softwares. 
Blood pressure measurements: Systolic blood pressure was monitored in conscious mice using a 
non-invasive tail-cuff photoplethysmography sytstem (BP-2000 Blood Pressure Analysis System, 
Visitech Systems). Blood pressures were assessed in a quiet environment at the same time of day, 
for a period of 7 days prior to the actual measurements, in order to allow the mice to adjust to the 
protocol. Each symbol represents the blood pressure value of individual mice. 
Isolation of single smooth muscle cells: Primary vascular smooth muscle cells were isolated 
essentially as described (53) using an enzymatic cocktail containing 9.6 U/ml papain (Sigma # 
P4762), 1200U/ml collagenase (Worthington # LS004176), 2.58U/ml elastase (Worthington # 
LS002292), 0.6% bovine serum albumin (BSA) and 1 mg/ml soybean trypsin inhibitor 
(Worthington # LS003587).  
Calcium imaging and Spark analysis: The resting calcium fluorescence was measured using the 
calcium indicator fura-2 AM (Invitrogen) (26) and the total amount of Ca2+ present in the rapidly 
releasable intracellular stores was determined as previously described (54). Calcium sparks were 
measured in cells loaded with 5 µM Fluo-4 using a Nikon A1R laser scanning confocal 
microscope (Nikon Instruments Inc. Melville, USA) with a 60× oil immersion Plan Apo VC 
Nikon objective (NA 1.4). Five sec duration linescan images (x,t) were acquired in resonant mode 
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at super high temporal resolution (7680 lps) with 512 pixels (0.05 µm/pixel) in the x- and 39936 
pixels (0.126 ms/pixel) in the t-direction using a pinhole size of 72.27 µm. Four to five images 
were taken at different positions across each cell. Fluo-4 was excited with a laser at 487 nm and 
the fluorescence emitted at 525+/-25 nm was recorded. Images were analysed using the open 
source image processor software Fiji (55). After binning 4X in the temporal axes, linescan images 
were run with the automated sparks processor plugin SparkMaster (56).  
Immunofluorescence: Cells were fixed with ice-cold methanol: acetone (1:1) for 30 min and 
processed as previously described (54). The primary antibodies used were: mouse anti-smooth 
muscle actin (Sigma #A5228), mouse anti-RyR1 (Thermo Scientific #MA3-925), rabbit anti-
Cav1.2 (Santa Cruz # sc-25686) and the secondary conjugates were anti-mouse Alexa Fluor 568 
and chicken anti-rabbit Alexa Fluor 488 (Lubio science). Nuclei were counterstained with DAPI 
(25-30 µM) for 5 min prior to mounting. Cells were examined by confocal microscopy using a 
Nikon A1R laser scanning confocal microscope with a 60× oil immersion Plan Apo objective. 
 Real Time qPCR and RT PCR: Total RNA was extracted and treated with deoxyribonuclease I 
(Invitrogen) as previously described (26). After reverse transcription using 1000-1500 ng of 
RNA, cDNA was amplified by quantitative real-time PCR with a 7500 Fast Real-Time PCR 
system (Applied Biosystems) using SYBR Green technology (fast SYBR green master mix, 
Applied Biosystems) and the following primers: RYR1 F: 5’-TCA CTC ACA ATG GAA AGC 
AG-3’; R: 5’-AGC AGA ATG ACG ATA ACG AA-3’; DES F: 5’-TGA GAC CAT CGC GGC 
TAA GA-3’ and R: 5’-GTG TCG GTA TTC CAT CAT CTC C-3’. Gene expression was 
normalized to desmin (DES) content as this marker is specifically expressed in muscle cells (30, 
57). RYR1 expression levels in mouse aorta, tail artery and mesenteric artery were compared to 
RYR1 expression levels in Extensor Digitorum Longus (EDL), that latter being the reference 
tissue set to 1. RYR1 expression in aorta was also investigated by semi-quantitative RT PCR as 
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previously described (26).  
Membrane potential measurements: Membrane potential measurements were performed using 
the potentiometric fluorescence dye Bis-Oxonol as described (58). Briefly, isolated arterial 
smooth muscle cells were plated on laminin: gelatin (1:10 ratio) pre-coated coverslips and 
allowed to attach for 20 min in a modified Krebs-Ringer solution (in mM: NaCl: 140; CaCl2: 0.5; 
KCl: 5; MgSO4: 1; HEPES: 10; Na2HPO4: 1; Glucose: 5.5 and Albumin 1%). Cells were loaded 
with the potentiometric fluorescence dye Bis-Oxonol (Molecular Probes, B438) in the presence or 
absence of 20 µM dantrolene at room temperature for 30-40 min. To calibrate the membrane 
potential cells were incubated with the Na+ ionophore gramicidin (10 µM) (Sigma, G 5002) and 
then exposed to different Na+ containing solutions (Supplementary Figure 5). The concentration 
ratios of Na+ and Choline were varied in order to maintain [Na+] + [Choline] = 144 mM. 
Theoretical values for membrane potential were calculated according to the formula: 
Em = 60 Log([Na+]o + [K+]o)/( [Na+]i + [K+]i)         (Eq 1) 
and considering the internal concentration of Na+ and K+ as described by Nelson et al. (18). 
Fluorescence was recorded every 0.5 min with a Nikon A1 plus confocal microscope, using a 
60X oil objective. Samples were illuminated with a Sapphire Laser at 488 nm and the 
fluorescence emitted at 525/50 nm was recorder. Fluorescence images were processed using the 
open source software Fiji.  
Statistical analysis and graphical software: Statistical analysis on the MCMDM1-VWD 
bleeding questionnaires was performed by converting raw bleeding scores to binary numbers for 
use in Fisher exact testing with 2-tailed p value (negative screening test ≤3, positive screening 
test ≥4). Mean scores were compared using Student’s t test. For all other experiments statistical 
analysis was performed using the Student's t test; means were considered statistically significant 
when the P value was <0.05. Data was processed, analysed and plotted using the software 
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OriginPro 8.6.0 (OriginLab Corporation). Images were assembled using Adobe Photoshop CS 
(version 8.0). 
Supplementary Information 
Supplementary Figure 1: RYR1Y522S female mice also exhibit prolonged bleeding times  
Supplementary Figure 2: Heart rate and systolic blood pressure are similar in WT and 
RYR1Y522S mice. 
 Supplementary Figure 3: Expression of RYR2 and RYR3 are not significantly different in the 
tail arteries of WT and RYR1Y522S mice.  
Supplementary Figure 4: Specificity of the anti-RyR1 antibodies used for IHC.  
Supplementary Figure 5:	  Membrane potential measurements using the fluorescence 
potentiometric probe Bis-Oxonol. 
Supplementary Table 1: Kinetic parameters of Sparks in arterial smooth muscle cells from WT 
and RYR1Y522S mice 
Supplementary Video 1:  Sparks in SMC from WT mice.  
Supplementary Video 2:  Sparks in SMC from RYR1Y522S mice.  
Supplementary Video 3:  Sparks in SMC from WT mice after treatment with 10 µM ryanodine. 
Supplementary Video 4:  Sparks in SMC from RYR1Y522S mice after treatment with 20 µM 
dantrolene.  
Supplementary Video 5: Sparks in SMC from RYR1Y522S mice after treatment with 250 nM 
Xestospongin C.   
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Figure Legends 
Figure 1. RYR1 mutations are associated with prolonged bleeding times. A. 
Scatterplot of MCMDM-1VWD bleeding scores for RYR1-mutated patients compared to related 
controls without the familial RYR1 mutation(s) (mean score 2.3 in cases compared to -0.4 in 
controls, P<0.005, Student’s t-test). Eight out of thirteen female patients had abnormal bleeding 
scores compare to 0/4 female controls (P<0.03, Student’s t-test). The mean bleeding score for 
female patients was 4.5 (range 2 to 9), and -1.3 (range -2 to 0) in controls (P<0.0005, Student’s t-
test).	  B. RYR1Y522S knock in MHS mice showed prolonged bleeding times that were reversed by 
dantrolene. Each symbol represents the bleeding time (in sec) of a single wild type (light grey) 
and RYR1Y522S (dark grey) mouse. Mice were either untreated (left panel), pre-treated with 10 
mg/Kg dantrolene prior to the experiment (central panel) or pre-treated with vehicle alone right 
panel. **P<0.05 Students t-test. C. Blood flow velocity in the caudal artery before and after 
incision. Each symbol represents the mean of 5 measurements performed on each mouse at the 
indicated time. Light grey symbols, WT mice; dark grey symbols, RYR1Y522S mice. *P<0.004 and 
*** P<0.0001 Student’s t test.	  
Figure 2. RyR1 is present at the mRNA and protein level in aortae and tail arteries and is 
localized close to the plasma membrane. A. RYR1 expression in skeletal muscle (SKM), aorta, 
tail (TA) and mesenteric artery (MA) was normalized to DES content, which is present in skeletal 
and smooth muscle cells (30). The numbers below the bars indicate number of mice used for the 
analysis. B. The presence of the Y522S mutation does not affect RYR1 expression as determined 
by qPCR. The numbers below the bars indicate number of mice used for the analysis. C. Total 
RNA was extracted from purified aortas and the expression of RYR1 was evaluated by RT-PCR. 
Digestion of the amplified RYR1 cDNA from wild-type mice (WT) yielded the uncut band of 
about 376 bp.  Digestion of the cDNA from heterozygous RYR1Y522S mice yielded two bands of 
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276 bp and 100 bp plus the uncut 376 bp band from the wild-type allele. Image is representative 
of 2 independent experiments with 2 mice analyzed per genotype. D. Phase contrast of an isolated 
primary vascular smooth muscle cell (left); confocal immunofluorescence on the same cell using 
a mouse antibody specific for smooth muscle actin followed by anti–mouse Alexa Fluor 569 
(middle) or DAPI to localize the nucleus (right). Images are representative of cells from 4 mice 
per genotype. E. Phase contrast on an isolated primary vascular smooth muscle cell (leftmost 
image). Confocal immunofluorescence of the same cell stained with mouse monoclonal anti-
RyR1 mAb followed by anti-mouse Alexa Fluor-568 (red), rabbit anti-Cav1.2 followed by anti-
rabbit Alexa Fluor-488 (green), DAPI (blue). Composite image showing co-localization of RyR1 
and Cav1.2 (rightmost image). Images are representative of cells from 4 mice per genotype. Scale 
bar = 10 µm. 
Figure 3. Arterial smooth muscle cells from RYR1Y522S mice exhibit smaller intracellular 
Ca2+ stores and a higher frequency of spontaneous Ca2+ sparks. A. Representative Fura-2 
traces of resting fluorescence ratios (340/380 nm) of primary vascular smooth muscle cells 
isolated from  WT (light grey) and a RYR1Y522S (dark grey) mice. B Mean resting fluorescence 
ratios from primary vascular smooth muscle cells isolated from 2 WT (n=20 cells) and 2 
RYR1Y522S knock in (n=20 cells) mice. The values were not significantly different. C. Total 
amount of Ca2+ in the thapsigargin/ionomycin-sensitive stores was significantly lower in vascular 
smooth muscle cells from 2 RYR1Y522S mice (n=20 cells) compared to those from 2 WT (n=20 
cells) mice. *P< 0.05 Student’s t test. Experiments were performed as described in (54). D. Top 
row (left) brightfield image and (right) fluo-4 fluorescent photomicrograph of an isolated smooth 
muscle cell. Bar indicates 10 µm. Bottom, representative pseudocolour and greyscale linescan 
images of spontaneous localized calcium release events (sparks) in vascular smooth muscle cells. 
Experiments were performed on cells from WT (top) and RYR1Y522S (bottom) mice. The color 
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scale indicates the fluorescence change calculated as the F/F0 ratio. The traces under the linescan 
images show the time course of the calcium sparks. Scale bars: vertical 10 µm, horizontal 100 
ms, pseudocolor F/F0. E. Mean (±SEM) spark frequency in VSMC from 6 WT (light grey, n=28 
cells) and 6 RYR1Y522S (dark grey, n=28) mice. **P<0.03; ***P< 0.0001 Student’s t test when 
comparing cells ± dantrolene and ± ryanodine  
Figure 4: Smooth muscle cells from RYR1Y522S mice are more hyperpolarized than those 
from WT mice, and schematic representation of RyR1 function in arterial smooth muscle 
cells. A. The resting membrane potential was measured using the potentiometric probe Bis-
Oxonol in VSMC from WT mice (7 controls, 2 + dantrolene)  and  RYR1Y522S mice (4 controls 
and 2 +dantrolene ) (see also Supplementary Figure 5). n indicates the number of individual cells 
that were assessed. Cells were either left untreated (control) or pretreated with 20 µM dantrolene 
for 30 minutes.* Mean resting membrane potential was significantly different between WT and 
RYR1Y522S mice (Student’s t-test P<0.05). B. Schematic representation of the mechanism leading 
to prolonged bleeding time due to RYR1 mutations. In normal conditions (left panel), early 
vasospasm occurring immediately after injury reduces bleeding (in coordination with platelets 
and coagulation factors not shown here). Mutations in RYR1 (right panel) result in 
hyperpolarization of the smooth muscle cell membrane potential, reducing the ability of vessels 
to contract and ultimately increasing the bleeding time. PM: Plasma Membrane, SR: 
Sarcoplasmic Reticulum, RyR1: Ryanodine Receptor Type 1, caBK: Calcium activated Potassium 
Channel. Blue balls: Potassium, Yellow balls: calcium sparks, WT: Wild Type, RyR1Y522S : MH 
knock-in. 
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Table 1. Genetic details, neuromuscular features, MCMDM-1VWD bleeding questionnaire 
scores, and bleeding phenotypes from patients with RYR1-related myopathies and their 
healthy relatives. 
F	  
P/
C	   S	   RYR1	  mutation(s)	   I	   NM	  
RYR1	  
+/-­‐	  
B
S	   Bleeding	  phenotype	  
	   	   	   	   	   	   	   	   	  
1	  
1.
1	   F	  
p.R2241X,	  p.D708N;	  
p.R2939K	  
A
R	  
MmD/
MH	   +	   5	   Severe	  menorrhagia;	  Postpartum	  bleeding	  
	   	   	   	   	   	   	   	   	  
	  
2.
1	   F	   p.G4638D	  
A
D	  
CCD/M
HS	   +	   6	   Severe	  menorrhagia;	  Postpartum	  bleeding	  
	  
2.
2	   F	   p.G4638D	  
A
D	  
CCD/M
HS	   +	   9	   Severe	  menorrhagia;	  Postpartum	  bleeding	  
	  
2.
3	   M	   -­‐	   -­‐	   -­‐	   -­‐	  
-­‐
2	   not	  applicable	  
	  
2.
4	   M	   -­‐	   -­‐	   -­‐	   -­‐	   3	  
Rectal	  bleeding	  (diverticulitis	  ?);	  Bleeding	  
after	  dental	  extraction	  
2	  
2.
5	   M	   -­‐	   -­‐	   -­‐	   -­‐	   2	   Rectal	  bleeding	  (colitis	  ?)	  
	  
2.
6	   M	   p.G4638D	  
A
D	  
CCD/M
HS	   +	   4	   Epistaxis;	  Easy	  bruising*	  
	  
2.
7	   M	   p.G4638D	  
A
D	  
CCD/M
HS	   +	   1	   Easy	  bruising*	  
	  
2.
8	   M	   -­‐	   -­‐	   -­‐	   -­‐	   0	   not	  applicable	  
	  
2.
9	   F	   -­‐	   -­‐	   -­‐	   -­‐	  
-­‐
1	   not	  applicable	  
	  
2.
10	   F	   -­‐	   -­‐	   -­‐	   -­‐	  
-­‐
2	   not	  applicable	  
	  
2.
11	   M	   -­‐	   -­‐	   -­‐	   -­‐	  
-­‐
1	   not	  applicable	  
	   	   	   	   	   	   	   	   	  
3	  
3.
1	   F	  
p.S1342G,	  p.A1352G,	  
p.T2787S	  
A
D	   ERM	   +	   2	   Menorrhagia;	  Epistaxis	  
	  
3.
2	   F	  
p.S1342G,	  p.A1352G,	  
p.T2787S	  
A
D	   ERM	   +	   2	   Menorrhagia;	  Oral	  cavity	  bleeding	  
	   	   	   	   	   	   	   	   	  
	  
4.
1	   F	   p.G2434R	  
A
D	  
ERM,	  
MHS	   +	   7	   Severe	  menorrhagia;	  Epistaxis	  
	  
4.
2	   F	   p.G2434R	  
A
D	  
ERM,	  
MHS	   +	   4	   Severe	  menorrhagia#	  
4	  
4.
3	   M	   -­‐	   -­‐	   -­‐	   -­‐	   0	   Epistaxis	  
	  
4.
4	   F	   -­‐	   -­‐	   -­‐	   -­‐	  
-­‐
2	   not	  applicable	  
	  
4.
5	   M	   p.G2434R	  
A
D	  
ERM,	  
MHS	   +	   3	   Epistaxis;	  Bleeding	  after	  dental	  extraction	  
	   	   	   	   	   	   	   	   	  
5	  
5.
1	   F	   p.H3981Y	  
A
D	   ERM	   +	  
1
3	   Severe	  menorrhagia;	  	  Postpartum	  bleeding*	  
	  
5.
2	   M	  
p.T4288_A4290dup;	  
p.H3981Y	  	  
A
D	   ERM	   +	   2	   Muscle	  haematoma	  after	  muscle	  cramps	  
	   	   	   	   	   	   	   	   	  
	  
6. F	   p.T4288_A4290dup	   A ERM	   +	   4	   Menorrhagia;	  Postpartum	  bleeding	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1	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6	  
6.
2	   F	   p.T4288_A4290dup	  
A
D	   ERM	   +	   4	  
Easy	  bruising;	  Oral	  cavity	  bleeding;	  GI	  
bleeding	  
	  
6.
3	   M	   p.T4288_A4290dup	  
A
D	   ERM	   +	   1	   Bleeding	  from	  minor	  wounds	  
	   	   	   	   	   	   	   	   	  
	  
7.
1	   M	   p.V4849I	  
A
D	   ERM	   +	  
-­‐
2	   not	  applicable	  
7	  
7.
2	   M	   p.V4849I	  
A
D	   ERM	   +	  
-­‐
1	   not	  applicable	  
	  
7.
3	   M	   p.I2321V;	  p.V4849I	  
A
D	   ERM	   +	   0	   not	  applicable	  
	  
7.
4	   M	   -­‐	   -­‐	   -­‐	   -­‐	   0	   not	  applicable	  
	  
7.
5	   F	   -­‐	   -­‐	   -­‐	   -­‐	   0	   not	  applicable	  
	  
7.
6	   M	   -­‐	   -­‐	   -­‐	   -­‐	   0	   not	  applicable	  
	  
7.
7	   M	   -­‐	   -­‐	   -­‐	   -­‐	   0	   not	  applicable	  
	   	   	   	   	   	   	   	   	  
	  
8.
1	   M	   p.R614C	  
A
D	   MHS	   +	   1	   Oral	  cavity	  bleeding	  
	  
8.
2	   M	   p.R2676W	  
A
D	   MHS	   +	  
-­‐
2	   not	  applicable	  
8	  
8.
3	   M	   p.R614C	  
A
D	   MHS	   +	  
-­‐
1	   not	  applicable	  
	  
8.
4	   M	   -­‐	   -­‐	   -­‐	   -­‐	  
-­‐
2	   not	  applicable	  
	  
8.
5	   F	   p.R2676W	  
A
D	   MHS	   +	   2	   Menorrhagia	  
	   	   	   	   	   	   	   	   	  
9	  
9.
1	   F	   p.R2454H	  
A
D	   MHS	   +	   4	  
Easy	  bruising;	  Postpartum	  bleeding;	  Muscle	  
hematoma	  
	  
9.
2	   M	   p.R2454H	  
A
D	   MHS	   +	  
-­‐
2	   not	  applicable	  
	  
	   	   	   	   	   	   	   	  
	  
Abnormal MCMDM-1VWD bleeding scores (>4) are highlighted in red. Patient 1.1 was 
deceased and the MCMDM-1VWD bleeding questionnaire was completed retrospectively 
based on information derived from the patient medical notes. *Three patients (2.6, 2.7, 5.1) 
were excluded from further statistical analysis because of abnormal von Willebrand factor 
levels (2.6, 2.7) and evidence of abnormal platelet function (5.1), respectively. #Patient 4.2 
reported improvement of bleeding symptoms following commencement of dantrolene 
treatment, which was prescribed for exertional myalgia. Two dominant heterozygous MHS-
related RYR1 mutations were running independently in families 5, 7 and 8. RYR1-mutated 
individuals in families 2 and 5 reported additional symptoms suggestive of smooth muscle 
involvement concerning both bladder and bowel (urinary incontinence, vesicoureteral reflux, 
“spastic colon”). Neuromuscular features from families 1, 2, 4, 6, 7 and 8 have been 
previously reported. F = Family; P/C = Patient/Control; I = Inheritance; NM = Neuromuscular 
phenotype; RYR1 +/- = RYR1 mutation carrier state; BS = MCMDM-1VWD bleeding score; 
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CCD = Central Core Disease; MHS = Malignant Hyperthermia Susceptibility; ERM = 
exertional rhabdomyolysis.  
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Supplementary Materials: 
 
 
Supplementary Figure 1: RYR1Y522S female mice also exhibit prolonged bleeding times. 
Each symbol represents the bleeding time (in sec) of a single wild type (light grey) and 
RYR1Y522S (dark grey) female mouse. *P<0.005 Students t-test. 
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Supplementary Figure 2: Heart rate and systolic blood pressure are similar in WT and 
RYR1Y522S mice. A. Heart rates were obtained while performing Echo Doppler in lightly 
anesthetized animals at different time points after incision of the caudal artery. Each symbol 
represents a WT mouse (light grey) and RYR1Y522S mouse (dark grey). There is a trend of 
higher heart rates in the RYR1Y522S mice but his did not reach statistical significance. B. 
Systolic blood pressure in non-anesthetized animals was determined as explained in the 
Methods section. No difference was observed between WT (light grey) and RYR1Y522S (dark 
grey) mice. 
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Supplementary Figure 3: Expression of RYR2 and RYR3 are not significantly different 
in the tail arteries of WT and RYR1Y522S mice. Expression levels of RYR2 and RYR3 were 
determined by qPCR as outlined in the Methods section. Gene expression was normalized to 
ß-tubulin. Results are the mean ± SEM of 3 replicates on tail arteries isolated from 4 different 
mice. Results are expressed as relative expression levels compared to RYR2 expression in 
mouse heart (panel A) and RYR3 expression in mouse diaphragm (panel B).  
  
	   39	  
 
 
Supplementary Figure 4: Specificity of the anti-RyR1 antibodies used for IHC: western 
blots of skeletal and cardiac total sarcoplasmic reticulum membranes using isoform 
specific anti-RyR antibodies.  Thirty micrograms of sarcoplasmic reticulum proteins from 
skeletal muscle (left lane) or heart (right lane) were separated on a 6% SDS PAG and blotted 
onto nitrocellulose. Blots were blocked with 1% blocking buffer (Roche) in TBS for 60 min 
and probed with 1:5000 dilution monoclonal anti-RyR1 specific mAb34-C (left panel) or anti-
RyR2 mAb C3-33 (right panel) for 60 min in TBST, rinsed 3 times with TBST, incubated 
with peroxidase-conjugate anti-mouse IgG (1:200,000 in TBST), rinsed 3 times and 
developed using the enhanced chemiluminescence kit from Thermo Scientific. As shown, 
under the experimental conditions used in our laboratory the anti-RyR1 mAb does not cross 
react with cardiac RyR2. The blot on the right shows a positive control for cardiac RyR2. 
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Supplementary Figure 5.	   Membrane potential measurements using the fluorescence 
potentiometric probe Bis-Oxonol. Left: Representative traces of the changes in fluorescence 
obtained in an arterial smooth muscle cells from WT mice (light symbols) and Heterozygous 
RYR1Y522S mice (dark symbols) expressed as Fluorescence Intensity arbitrary units (AU). The 
arrows indicted addition of Gramicidin or the indicated [Na+] in mM. Right: Values derived 
from Equation 1 (Methods section) with the best linear fitting regression (R2=0.90; Y = 
0.0065X + 2.6525) of the log of the fluorescence obtained at each [Na+].	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Supplementary Table I.   
 
 
Detailed analysis of full kinetic parameters of sparks in vascular smooth muscle cells 
from WT and RYR1Y522S mice. 
 
Spark Morphology 
 
Amplitude 
(DF/F0) 
FWHM 
(µm) 
FDHM 
(ms) 
Full Widht 
(µm) 
Full Dur 
(ms) 
TtP (ms) Tau (ms) 
Freq 
(Sparks/image) 
N† 
WT 0.83±0.01 1.72±0.04 22.09±0.75 4.38±0.10 69.93±2.05 20.72±0.64 128.56±33.66 6.96±0.49 877 
RyR1Y522S 0.79±0.01* 1.56±0.03* 19.52±0.64* 4.04±0.07* 59.32±1.32* 19.76±0.54 72.81±9.13 10.68±0.55* 1388 
• Values are expressed as mean ± SEM. * = P< 0.05 Student’s t-test. Experiments were 
performed on  28 cells isolated from 6 WT and 6 RYR1Y522S mice respectively.  
• †N indicates the number of individual sparks that were analysed 
 
 
 
	  
	  
 
